Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,036 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05193240Recruiting
Swallowing test to predict vocal cord paralysis after lung surgery
This study checks whether a simple swallowing test can forecast vocal cord paralysis after lung surgery, compared with a camera exam of the throat. If predictions are accurate, it may help doctors prevent or plan treatment for swallowing and voice problems.
RouenAges 18 years+ - NCT06361589Recruiting
Lorlatinib for advanced ALK-positive lung cancer
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Chengdu, SichuanAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Daphne, AlabamaAges 18 years+ - NCT05229614RecruitingPhase 2
Immunotherapy plus carbon ion radiation for stable solid tumors
This trial studies whether adding carbon ion radiation to ongoing immunotherapy can help people whose cancer is currently stable. It targets solid cancers where scans show the disease is not growing quickly, aiming to improve control without causing unsafe side effects.
DarmstadtAges 18 years+ - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+ - NCT05632809RecruitingPhase 2
Boosting immune cells after lung cancer chemoradiation
This trial studies whether a medicine called NKTR-255 can help restore and strengthen immune cells after standard chemoradiation for non-small cell lung cancer. The goal is to improve how well the body can fight the cancer after initial treatment.
Houston, TexasAges 18 years+ - NCT05736029Recruiting
Using blood and tumor data to predict cancer treatment response
This study looks at “multiomics” information (many types of biological data, like blood and lab markers) to predict how well cancer treatments may work for you. It may help doctors choose better treatments in the future based on what your body is doing during therapy.
Dallas, TexasAges 18 years+ - NCT05934032Recruiting
Genomic medicine for non-surgical lung cancer
This trial is part of a lung cancer network that uses genetic (DNA) testing to better understand and treat non-surgical lung cancer. You might be eligible if you have certain stages of non-small cell lung cancer and can consent to participate.
CologneAges 18 years+ - NCT06528847RecruitingPhase 2
Adjuvant Benmelstobart for stage IB, grade 3 lung adenocarcinoma
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT06869122Recruiting
Microwave ablation for lung cancer in surgery candidates
This trial tests a minimally invasive procedure that uses microwave energy to destroy lung tumors. It is for people who are already candidates for surgery but may want a less invasive option.
MilanAges 18 years+ - NCT07120698RecruitingPhase 2
MRD-guided sintilimab after surgery for NSCLC
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Guangzhou, GuangdongAges 28–75 - NCT07316062Recruiting
Lung cancer treatment study in China
This study looks back at the medical records of people in China diagnosed with early-stage lung cancer (Stage I–III) to learn more about the disease and how it is treated. It does not involve any new treatments or tests—just reviewing information that was already collected during your care.
BeijingAges 18 years+ - NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
Nanchang, JiangxiAges 18–99 - NCT07399210Recruiting
Detecting lung nodule cancer with a blood test
This study aims to see if a blood test can tell if a lung nodule is cancerous or not. It may help doctors avoid unnecessary procedures.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT06324110Enrolling by invitation
Lung cancer screening follow-up study
This study is testing whether a centralized support program helps people get regular lung cancer screening. If you are at risk for lung cancer and have had a screening CT scan at one of the participating health centers, this study may help improve care.
Seattle, WashingtonAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100 - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT03192501Recruiting
Using prior scans to guide cancer treatment choices
This trial tests whether using existing “PACS” scan images to guide individualized cancer treatment (compared with standard care) can improve outcomes for people with advanced or metastatic cancer. It may help doctors make more precise treatment decisions using your past imaging.
Guangzhou, GuangdongAges 18–70 - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Sarasota, FloridaAges 18 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT05407168Recruiting
Conversation tool to help people make lung cancer decisions
This trial tests a low-reading-level conversation tool meant to help people with suspected lung cancer understand and make treatment decisions with their clinicians. It may help by making discussions clearer and easier to follow.
Hillsboro, OregonAges 18–99
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,036 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.